OTCQB: OXIS

Immunotherapy for the Treatment of Cancer

Targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma and more with highly potent biopharmaceutical drugs designed for targeted therapy.

View Product Pipeline

About

OXIS International, Inc., develops and commercializes innovative immunotherapeutic for the treatment of cancer and other unmet medical needs.

learn more
About
Technology

Technology

Antibody-drug conjugates are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of cancer.

learn more

Latest News

Oxis International Issues Letter to Shareholders
Jul 13, 2016 • 4:22 EDT | Read More

Oxis Adds New Patients in Phase 1/Phase 2 Clinical Trial of Key Cancer Drug OXS-1550
Jul 11, 2016 • 4:09 EDT | Read More

Investors

OXIS International Inc. OTCQB: OXIS
Loading... Change
Loading... Volume
Loading... 52 Week Range